Pancreatic cancer is characterized by early metastatic spread, but the process of tumor cell dissemination is largely unknown. In this study we show that the soluble protein pancreatic adenocarcinoma upregulated factor (PAUF) has an important role in the metastasis and progression of the disease. Variations in the level of PAUF, either by overexpression or knockdown, resulted in altered migration, invasion and proliferation capacity of pancreatic cancer cells. Moreover, depletion of PAUF in metastatic cells dramatically abrogated the spread of the cells to distant organs in an orthotopic xenograft mouse model. PAUF elicited the activation of the extracellular signalregulated kinase (ERK), c-Jun N-terminal kinase (JNK) and AKT intracellular signaling cascades and consequently their downstream transcription factors in an autocrine manner. Genome-wide expression analysis revealed that C-X-C chemokine receptor type 4 (CXCR4) expression was induced by PAUF overexpression but was repressed by PAUF knockdown. The PAUF-mediated increase in cancer cell motility was attenuated by the CXCR4 inhibitor, AMD3100, or by anti-CXCR4 antibody. Furthermore, immunohistochemical analysis of pancreatic tumor tissues clearly showed a significant positive correlation between PAUF and CXCR4 expression. Collectively, these findings indicate that PAUF enhances the metastatic potential of pancreatic cancer cells, at least in part, by upregulating CXCR4 expression.
Introduction
Pancreatic cancer is one of the deadliest human tumors with approximately 4% of the 5-year survival rate (Ghaneh et al., 2008; Maitra and Hruban, 2008) . Early diagnosis of pancreatic cancer is infrequent and at diagnosis most patients have locally advanced or metastatic disease, which is surgically inoperable and resistant to conventional chemotherapy and radiotherapy. The aggressive metastatic nature of pancreatic cancer is attributed, in part, to the propensity of the disease to metastasize even when the tumor size is small (Korc, 2007) .
Little is known about the molecular mechanisms controlling pancreatic cancer metastasis. Pancreatic cancer cells are characterized by the overexpression of many growth factors to modulate tumor progression and metastasis (Ozawa et al., 2001; Ghaneh et al., 2008) . Increased level of the epidermal growth factor receptor 1 and its ligands, epidermal growth factor and transforming growth factor-a, activates the MEK/extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase/AKT and signal transducers and activators of transcription signaling pathways to promote survival and progression (Korc et al., 1992; Marshall, 2006) . Transforming growth factor-b is upregulated (Friess et al., 1993) and induces the expression of connective tissue growth factor, a metastasis factor known to interact with integrin receptors (Grotendorst et al., 1996; Gao and Brigstock, 2005; Bennewith et al., 2009) . In another study, overexpression of neutrophil gelatinaseassociated lipocalin reduces tumor volume and distant metastasis by blocking cell adhesion and invasion (Tong et al., 2008) .
Pancreatic cancer is also characterized by extensive desmoplasia, which causes aberrant epithelial-stromal interactions, and this unique tumor microenvironment is thought to facilitate the metastatic potential of the tumor (Korc, 2007) . For instance, insulin secreted from endocrine islets may bind insulin-like growth factor 1 receptor that is overexpressed on cancer cells to elicit the invasive and metastatic capabilities of the cancer (Lopez and Hanahan, 2002) . Similarly, nerve growth factors from stromal nerve fibers bind and activate their receptors on cancer cells to promote proliferation and invasion of the cells along the neural tissue (Okada et al., 2004) . Both the cancer cell-derived and the stromal cell-derived glypican-1, a co-receptor for heparin-binding growth factors, are found to be important for efficient angiogenesis and metastasis of the cancer (Aikawa et al., 2008) .
A recent study of tumor stem cells showed that a subpopulation of CD133 þ CXCR4 þ pancreatic cancer stem cells is essential for tumor metastasis and that elimination of this subpopulation abrogates the metastatic activity of pancreatic cancer cells (Hermann et al., 2007) . Furthermore, the C-X-C chemokine receptor type 4 (CXCR4) was shown to increase liver and lung metastasis in a mouse model of pancreatic cancer (Saur et al., 2005) . Together, these findings suggest a role for CXCR4 in organ-specific pancreatic cancer metastasis (Zlotnik, 2008) .
Previously, we reported that a novel secreted protein, termed pancreatic adenocarcinoma upregulated factor (PAUF), is overexpressed in pancreatic ductal adenocarcinoma and has a role in tumorigenesis in xenograft mouse models (Kim et al., 2009) . In this study, we analysed PAUF function in the metastatic spread of human pancreatic cancer cells. Our results provide lines of evidence that PAUF has a crucial role in pancreatic cancer metastasis and progression and that the function involves upregulated CXCR4 expression.
Results
Pancreatic adenocarcinoma upregulated factor (PAUF) enhances the motility and invasiveness of pancreatic cancer cells in vitro We established a set of human pancreatic cancer cell lines in which PAUF was stably up-or downregulated. Cell lines, for either overexpression or knockdown, were selected on the basis of their endogenous levels of PAUF, as we have described previously (Kim et al., 2009) . The Panc-1 and MiaPaCa-2 cell lines, which show low PAUF level, were stably transfected with a PAUFexpression plasmid to generate the PAUF overexpressing cell lines Panc-1_PAUF and MiaPaCa-2_PAUF, respectively. Panc-1_Mock and MiaPaCa-2_Mock are the stable cell lines with a control plasmid. For PAUF knockdown studies, the CFPAC-1 and BxPC-3 cell lines, which express PAUF at quite a high level, were stably introduced with a PAUF-specific short hairpin RNA (shRNA) to generate the cell lines CFPAC-1_shPAUF and BxPC-3_shPAUF, respectively. CFPAC-1_shCtrl and BxPC-3_shCtrl are the stable cell lines with a control shRNA. Establishment of the overexpression or knockdown stable cell lines was confirmed using western blot analysis of the culture supernatants ( Figure 1a) .
We first characterized the stable cell lines by carrying out migration assays to examine the effects of PAUF on the motility of pancreatic cancer cells. Compared with their respective controls, migration activity of Panc-1_PAUF and MiaPaca-2_PAUF was dramatically enhanced (Figure 1b) , whereas that of CFPAC-1_shPAUF and BxPC-3_shPAUF was significantly diminished (Figure 1c ). The invasiveness of Panc-1_PAUF and MiaPaca-2_PAUF was enhanced compared with controls, whereas that of CFPAC-1_shPAUF and BxPC-3_shPAUF was reduced (Figures 1b and c) . When we examined the effect of PAUF on pancreatic cancer cell growth, PAUF overexpression stimulated the proliferation of the Panc-1 cell line, whereas the effect on the MiaPaCa-2 cell line was only marginal (Figure 1d ). By comparison, PAUF knockdown inhibited the proliferation of the CFPAC-1 and BxPC-3 cell lines. Together, these in vitro results suggest that PAUF could potentiate the progression of pancreatic cancer and induce metastasis by enhancing the motility and invasiveness of cancer cells.
Pancreatic adenocarcinoma upregulated factor (PAUF) stimulates the metastasis of pancreatic cancer cells in vivo To examine the in vivo relevance of the in vitro effects of PAUF, we examined tumor progression in xenograft mouse models. When we accessed the subcutaneous tumor formation after injection of Panc-1_PAUF or Panc-1_Mock cells into athymic nude mice, one-third (5 out of 15) of the mice injected with Panc-1_PAUF cells showed aggressive metastasis at autopsy, whereas mice injected with the control cells (n ¼ 13) showed tumors only at the sites of injection (data not shown). To visualize the effect of PAUF on tumor metastasis in vivo, Panc-1_PAUF or Panc-1_Mock cells were stably introduced with the firefly luciferase gene and used in in vivo bioluminescence imaging analysis. At 2 months after subcutaneous injection with the luciferase-expressing Panc-1 cell lines, two of the four mice injected with Panc-1_PAUF cells, but none with Panc-1_Mock cells, showed wide-spread luminescence signal throughout the body (Figure 2a) . PAUF was detected in the sera of the metastasized mice but not in that of the non-metastasized mice (Figure 2a) . Ex vivo imaging of organs removed from the Panc-1_PAUF mice with metastasis revealed that the cells had spread into many organs, including the spleen, stomach, kidney, colon, liver, pancreas and diaphragm (Figure 2a ). This finding, together with the fact that the original Panc-1 cell line is derived from primary pancreatic tumor and hardly metastasizes (Lieber et al., 1975) , suggests that PAUF acts as a potent stimulator of metastasis in pancreatic cancer.
To confirm the metastatic effect of PAUF in the relevant organ environment, we analysed the effect of PAUF knockdown on metastasis in an orthotopic pancreatic tumor model using CFPAC-1 cells, which originated from liver metastasis of pancreatic cancer (Schoumacher et al., 1990) . Bioluminescence imaging analysis revealed that mice injected with CFPAC1_shPAUF (n ¼ 14) had a markedly low level of metastasis in limited regions compared with the strong and broad bioluminescence signal in mice injected with CFPAC-1_shCtrl (n ¼ 13; Figure 2b ). Ex vivo imaging results clearly indicate that the ability of CFPAC-1 cells to metastasize to distant organs, including the kidney, colon, stomach and liver, was drastically abrogated by PAUF knockdown (Figure 2c ). The local invasion of CFPAC-1_shPAUF cells to the spleen was also significantly inhibited. In addition, PAUF knockdown inhibited the proliferation of CFPAC-1 cells in the primary tumor sites, as evidenced by the reduced luminescence signal from ex vivo imaging analysis ( Figure 2d ) and proliferating cell nuclear antigen level by immunohistochemical analysis (Figure 2e ). Collectively, both in vivo and in vitro results indicate that PAUF has an important role in the metastasis and progression of pancreatic cancer cells.
Pancreatic adenocarcinoma upregulated factor (PAUF) acts in an autocrine manner to modulate the intracellular signaling pathways of pancreatic cancer cells As PAUF is a secreted protein, we sought to determine whether PAUF affects the intracellular signaling cascades of pancreatic cancer cells in an autocrine manner by using a recombinant PAUF protein (rPAUF). The invasiveness of Panc-1 and CFPAC-1 cells was stimulated by rPAUF in a concentrationdependent manner (Figure 3a) , which is in agreement with our results obtained by PAUF overexpression (see Figure 1b ). In addition, the PAUF-induced invasiveness of Panc-1 cells was attenuated by the treatment of anti-PAUF antibody (Figure 3b ). Three different normal human cell lines that we tested did not show any significant alteration in cell migration or invasion by rPAUF (Supplementary Figure S1) . These results indicate that the secreted PAUF has a significant role in the motility of pancreatic cancer cells. We reasoned that the altered nature of pancreatic cancer cells induced by PAUF might have originated from changes in the intracellular signaling cascades, which are frequently dysregulated during tumor progression and metastasis (Reddy et al., 2003; Huang et al., 2004) . Treatment of Panc-1 and CFPAC-1 cells with rPAUF induced the rapid and transient activation of ERK, c-Jun N-terminal kinase (JNK) and AKT ( Figure 3c ). MEK1/2, the mitogen-activated protein kinase kinases upstream of ERK, showed the same rapid and transient activation by rPAUF as did ERK.
Stable overexpression of PAUF also resulted in the activation of ERK, JNK and AKT, whereas the knockdown of PAUF expression reduced the levels of activated ERK and AKT (data not shown). The PAUF-induced invasiveness of Panc-1 cells was significantly, but not completely, attenuated by the MEK/ERK signaling inhibitor PD98059, the JNK signaling inhibitor SP600125 and the AKT inhibiter LY294002 (Figure 3d ). Thus, PAUF activates the ERK, JNK and AKT signaling pathways and each pathway contributes to the motility of pancreatic cancer cells. Bioluminescence images in live, anesthetized mice and ex vivo images of organs from a metastasized Panc-1_PAUF mouse are shown. PAUF level was determined using western blot analysis of sera from xenograft mice (mice M1, M2 and M3 were injected with Panc-1_Mock and mice P1, P2, P3 and P4 with Panc-1_PAUF) using antibody against PAUF. PAUF was detected in the sera of metastasized mice (P3 and P4). (b-e) CFPAC-1_shPAUF or CFPAC-1_shCtrl cells stably expressing the firefly luciferase gene were injected into the pancreas of nude mice (shPAUF, n ¼ 14; shCtrl, n ¼ 13). Total flux (mean±s.e.) from bioluminescence imaging of in vivo whole body (b), ex vivo metastatic organs (c) and ex vivo primary pancreatic tumors (d) was measured on the day 23 after orthotopic implantation of pancreatic cancer cells at autopsy. Error bars represent s.e. *Po0.05; **Po0.01. (e) Primary tumors were sectioned for immunohistochemical staining to detect PAUF and proliferating cell nuclear antigen (PCNA).
Pancreatic adenocarcinoma upregulated factor (PAUF) activates transcription factors
The ERK and JNK signaling pathways transmit external signals to the nucleus and activate a number of transcription factors to result in the changes in gene expression required for diverse cellular processes, including tumor progression and metastasis (Reddy et al., 2003; Karin and Gallagher, 2005) . As shown in Figure 4a , western blot analyses revealed that rPAUF activated p90RSK, a downstream effector of the ERK signaling cascade (Anjum and Blenis, 2008) , and subsequently the p90RSK target transcription factors, CREB and ELK-1. ELK-1 is known to be activated by the ERK and JNK signaling pathways (Hsu et al., 2004) . The transcription factors c-Jun and ATF2, which are downstream targets of JNK signaling cascade, were also activated. The introduction into pancreatic cancer cells of the luciferase reporter gene linked to the upstream element CRE (a binding sequence of CREB), SRE (a binding sequence of ELK-1) or AP1 (a binding sequence of c-Jun/ATF2), resulted in a significant increase in luciferase activity by rPAUF (Figure 4b ).
Finally, PD98059, SP600125 and LY294002 blocked the rPAUF-mediated activation of their respective targeting signaling cascades (Figure 4c ). Collectively, our results indicate that PAUF acts on pancreatic cancer cells in an autocrine manner to activate transcription factors that are involved in tumor progression and metastasis.
Pancreatic adenocarcinoma upregulated factor (PAUF) enhances the expression of CXCR4 Having shown that PAUF activates the transcription factors that are involved in cancer, we next screened for genes whose expression levels were altered by PAUF through genome-wide expression analysis of pancreatic cancer cells. As shown in Figure 5a , the expression of 96 genes was increased by more than twofold in Panc-1_PAUF than in Panc-1_Mock and concurrently decreased by more than twofold in CFPAC-1_shPAUF than in CFPAC-1_shCtrl (the upregulated genes by PAUF are listed in Supplementary Table 1 ). In contrast, 32 genes were repressed in Panc-1_PAUF and induced in CFPAC-1_shPAUF (the downregulated genes by PAUF are listed in Supplementary Table 2 ). The genes induced by PAUF included those with functions in cancer progression and metastasis: inter-cellular adhesion molecule 1, epidermal growth factor receptor, histone deacetylase 3, endothelin receptor type B, mitogen-activated protein kinase kinase kinase 8, cyclin-dependent kinase 6, palladin, integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) and CXCR4. Among the genes induced, we noticed the chemokine receptor CXCR4, which is implicated in the organ-specific metastasis of a diverse range of human cancer types, including pancreatic adenocarcinoma (Saur et al., 2005; Koizumi et al., 2007) . Western blot analysis of cell lysates confirmed that the CXCR4 protein level was increased by PAUF overexpression and decreased by PAUF knockdown (Figure 5b) . Moreover, immunohistochemical analysis of primary tumors removed from orthotopic xenograft nude mice injected with CFPAC-1 cells indicated that PAUF knockdown decreased the level of CXCR4 in vivo (Figure 5c ). We then examined whether PAUF-induced Figure 3c , were used for western blot analysis with the respective p-p90RSK, p90RSK, p-CREB, CREB, p-ELK-1, ELK-1, p-c-Jun, c-Jun, p-AFT2 or ATF2 antibody. (b) Panc-1 cells were transfected with the firefly luciferase reporter plasmid containing the upstream element CRE, SRE or AP1. After 24 h of transfection, cells were starved for 16 h, and then treated with recombinant PAUF (rPAUF, 6 nM) or PBS for 2 h. Firefly luciferase activity was determined and then normalized to Renilla luciferase activity. Data represent mean values ± s.e. *Po0.05; **Po0.01. (c) Serum-starved Panc-1 cells were incubated with PD98059 (50 mM), SP600125 (20 mM), LY294002 (50 mM) or dimethylsulfoxide (DMSO) for 2 h and then with rPAUF (6 nM) or phosphate buffered saline (PBS) for 10 min. Cell lysates were prepared and used for western blot analysis with the respective p-ERK, ERK, p-p90RSK, p90RSK, p-c-Jun, c-Jun, p-ATF2, ATF-2, p-AKT or AKT antibody.
A novel metastasis factor of pancreatic cancer Y Lee et al CXCR4 expression was responsible for the increased pancreatic cancer cell motility. PAUF-induced motility was attenuated by AMD3100, a specific CXCR4 antagonist (Clercq, 2003) in a concentration-dependent manner (Figure 5d ). In another experimental setting, the PAUF-induced motility of Panc-1 cells was diminished by the treatment with anti-CXCR4 antibody, but not with control antibody (Figure 5e ). These data show that PAUF induces CXCR4 expression, which contributes to PAUF-mediated stimulation of motility of pancreatic cancer cells.
CXCR4 expression is correlative to pancreatic adenocarcinoma upregulated factor (PAUF) expression in pancreatic tumor tissues
To determine the clinical relevance of the PAUF-induced CXCR4 expression, we carried out immunohistochemical A novel metastasis factor of pancreatic cancer Y Lee et al analysis on 32 pancreatic adenocarcinoma tissue specimens (Figure 6a ). In agreement with a previous report (Koshiba et al., 2000) , CXCR4 expression was detected in 71.9% of pancreatic tumors (23 out of 32). The immunopositive ratio of PAUF was 84.4% (27 out of 32). The results, as shown in Figure 6b , reveal a significant positive correlation between the expression levels of PAUF and CXCR4. CXCR4 expression was detected along with PAUF expression in most of the human pancreatic tumor tissues (23 out of 27). None of the PAUF-negative tumor tissues showed CXCR4 expression, whereas all of the CXCR4-positive tissues expressed PAUF. Interestingly, PAUF expression was detected in tumor cells at the invasive front in several specimens (Figure 6c ), further implicating a role for PAUF in aggressive metastasis of pancreatic cancer cells. These immunohistochemical results, together with the data that CXCR4 contributes to PAUF-mediated cell motility, suggest a model in which PAUF functions in the metastasis of human pancreatic adenocarcinoma by inducing CXCR4 expression.
Discussion
In this study we provide five lines of evidence for the identification of PAUF, a novel soluble protein expressed in pancreatic ductal adenocarcinoma, as an important factor in pancreatic cancer metastasis. First, the degree of PAUF expression correlated positively with the migratory potential of pancreatic cancer cells in vitro. Second, PAUF knockdown dramatically inhibited the metastasis of pancreatic cancer cells to distant organs in vivo. Third, PAUF activated intracellular signaling cascades and, in turn, their downstream transcription factors, resulting in increased expression of genes involved in tumor progression and metastasis. Fourth, the expression of CXCR4 was induced by PAUF and repressed by PAUF-specific shRNA, and the PAUF-enhanced motility of cancer cells was diminished by a CXCR4 antagonist and anti-CXCR4 antibody. Finally, CXCR4 expression correlated closely with PAUF expression in pancreatic cancer tissues from patients. Organ-specific metastases can be mediated by the interaction of chemokine or cytokine receptors on cancer cells and their ligands that are abundant in predetermined metastatic locations (Mu¨ller et al., 2001; Mashino et al., 2002; Taichman et al., 2002; Jones et al., 2006) , by the interaction between specific proteins on the surface of cancer cells and the target organ endothelium (Brown and Ruoslahti, 2004) , and by the tumor-secreted humoral factors that establish specific microenvironments in future tumor metastatic sites, thereby, preparing the premetastatic niche for the arrival of cancer cells (Kaplan et al., 2005; Hiratsuka et al., 2006, . CXCR4 has an important role in the organspecific metastasis of many cancer types, including the breast, colon and prostate tumors, and is associated with a poor patient survival (Balkwill, 2004; Burger and Kipps, 2006; Zlotnik, 2006 Zlotnik, , 2008 . CXCR4-positive cancer cells migrate toward distant organs in response to a gradient of stromal cell-derived factor-1, the specific ligand of CXCR4, to form metastatic tumors. Elevated CXCR4 expression has been shown in pancreatic tumors and correlates with an advanced cancer stage and metastasis with a poor overall survival (Koshiba et al., 2000; Marchesi et al., 2004; Wehler et al., 2006; Wang et al., 2008) . In line with these previous reports, our immunohistochemical results indicate CXCR4 expression in pancreatic tumor tissues. CXCR4 expression increases metastatic potential of pancreatic cancer cells in vivo, resulting in liver and lung metastasis in a mouse model (Saur et al., 2005) , whereas CXCR4-specific shRNA or zerumbone, a compound that negatively regulates CXCR4 expression, inhibits pancreatic cancer cell invasion (Sung et al., 2008; Wang et al., 2008) . Furthermore, it is suggested that a subpopulation of migrating CD133 þ CXCR4 þ pancreatic cancer stem cells is essential for tumor metastasis (Hermann et al., 2007) . These results indicate an important role for CXCR4 in the metastasis of pancreatic cancer, but do not suggest any clinically relevant causal factor for the induction of CXCR4 expression. In this study we report that PAUF, which is expressed in pancreatic cancer cells, induces CXCR4 expression in an autocrine manner in vitro, and that PAUF-specific shRNA inhibits CXCR4 expression in an orthotopic mouse model. Furthermore, CXCR4 is detected only in PAUF-positive pancreatic tumor tissues. The induction of CXCR4 expression by PAUF in pancreatic cancer is reminiscent of recent findings regarding the regulation of CXCR4 expression in breast cancer cells. Vascular endothelial growth factor and hepatocyte growth factor promote breast cancer cell invasion by inducing CXCR4 expression in an autocrine and paracrine manner, respectively (Bachelder et al., 2002; Matteucci et al., 2005) . Another report describes the enhancement of CXCR4 expression by the human epithelial growth factor receptor 2, which is required for its mediated invasion of breast cancer cells in vitro and lung metastasis in vivo (Li et al., 2004) . Therefore, we propose a model in which PAUF enhances the metastatic potential of pancreatic cancer cells, and possibly mediates organ-specific metastasis, at least in part, by upregulating CXCR4 expression.
The mechanism underlying the PAUF-promoted increase in CXCR4 expression remains to be elucidated. Previous reports indicate that multiple mechanisms act in a coordinated manner to regulate CXCR4 expression (Benovic and Marchese, 2004) . In breast cancer cells, the human epithelial growth factor receptor 2-mediated increase in CXCR4 expression seems to involve both the increased translation of CXCR4, through activation of the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway, and the attenuated CXCR4 degradation, by inhibiting ubiquitination of the receptor on activation (Li et al., 2004) . In addition to the translational and post-translational regulation, CXCR4 expression also seems to be controlled at the transcriptional level as human epithelial growth factor receptor 2 can activate the AKT/nuclear factor-kB pathway, and nuclear factor-kB subsequently promotes breast cancer metastasis by inducing the transcriptional activation of CXCR4 (Zhou et al., 2000; Helbig et al., 2003) . In renal cell carcinoma, the overexpression of the hypoxiainducible factor-1a or the functional loss of its suppressing von Hippel-Lindau protein results in CXCR4 expression (Staller et al., 2003; Zagzag et al., 2005) . Our data show that, in pancreatic cancer cells, the ERK, JNK and AKT signaling pathways are activated by overexpression of PAUF or treatment of rPAUF, culminating in activation of several downstream transcription factors and increased CXCR4 transcription. It is possible that the signaling pathways affected by PAUF regulate CXCR4 expression in a coordinated manner. In support of this notion, PAUF-induced invasiveness of pancreatic cancer cells is significantly, but not completely, attenuated by treatment with PD98059, SP600125 or LY294002. Recent reports reveal that the MEK/ERK and AKT/mammalian target of rapamycin signaling pathways cooperate to promote the malignant transformation and survival of the transformed cells (McCubrey et al., 2006) , and that the simultaneous inhibition of both pathways results in substantially enhanced antitumor effects in mouse models of prostate cancer (Carracedo et al., 2008; Kinkade et al., 2008) . It is noteworthy that our western blot analysis or luciferase reporter assay failed to show any significant alteration in the activities of mammalian target of rapamycin, nuclear factor-kB and hypoxiainducible factor-1 by PAUF (our unpublished data), thus indicating that the mechanism underlying the control of CXCR4 expression in pancreatic cancer cells differs from that in breast or renal cancer cells. Efforts are currently underway to understand the mechanism of the induced CXCR4 expression by PAUF.
In conclusion, PAUF is required for the metastasis of pancreatic cancer cells to distant organs, thus providing a novel target for therapeutic intervention to treat human pancreatic cancer, in which conventional methods using cytotoxic chemotherapy and radiotherapy are unsuccessful. We are currently validating the potential of PAUF as a therapeutic target by means of anti-PAUF monoclonal antibodies. The issues that remain to be resolved include identification of the receptor(s) responsible for the intracellular signaling cascades activated by PAUF, determination of the mechanism underlying overexpression of PAUF in cancer cells and elucidation of the function of PAUF in normal cells.
Materials and methods

Cell lines and materials
The human pancreatic cancer cell lines, Panc-1, MiaPaCa-2, CFPAC-1 and BxPC-3, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 2. 5% horse serum, Iscove's modified Dulbecco's medium with 10% fetal bovine serum and RPMI with 10% fetal bovine serum, respectively. All the cell lines were obtained from the ATCC (Manassas, VA, USA) and maintained in a humidified incubator at 37 1C with 5% CO 2 . To generate cell lines overexpressing PAUF, the coding region of PAUF was amplified by PCR using the primers 5 0 -TTGGGATCCGTAT AAAGGCGATGTGGAGG-3 0 and 5 0 -ACCATCTAGAGCG ACCCACGGGTGAGT-3 0 . The PCR product was cloned into the BamHI and XbaI sites of pcDNA3.1( þ )-MycHis (Invitrogen, Carlsbad, CA, USA) to produce the PAUF-expression plasmid pcDNA3.1( þ )-PAUF-MycHis. Panc-1 and MiaPaCa-2 cells were transfected with pcDNA3.1( þ )-PAUF-MycHis or pcDNA3.1( þ )-MycHis using Lipofectamine (Invitrogen). Stably transfected clones were selected using G418. To generate the PAUF knockdown cell lines, PAUF-specific shRNA (5 0 -CCTTGGCATCAAGAGCATT-3 0 ) was cloned into the lentiviral vector shLenti2.4G (Macrogen, Seoul, Korea) to produce shLenti2.4G-PAUF. The lentiviral vector shLenti2.4G-Control containing control shRNA (5 0 -AATCGCATAGCGTATGCCGTT-3 0 ) was from Macrogen. After introducing shLenti2.4G-PAUF or shLenti2.4G-Control into BxPC-3 and CFPAC-1 cells, stable shRNA-expression clones were selected using puromycin. At least three independent clones were analysed for each stable cell line.
PD98059, SP600125 and LY294002 were purchased from Cell Signaling (Beverly, MA, USA), AMD3100 was from Sigma (Saint Louis, MO, USA), D-luciferin was from Regis Technologies (Morton Grove, IL, USA) and Matrigel was from BD Biosciences (San Jose, CA, USA). Antibodies against ERK, p-ERK, JNK, p-JNK, AKT, p-AKT, MEK1/2, p-MEK1/2, p90RSK, p-p90RSK, CREB, p-CREB, ELK-1, p-ELK-1, c-Jun, p-c-Jun, ATF2 and p-ATF2 were from Cell Signaling. Anti-b-actin antibody was from Santa Cruz (Santa Cruz, CA, USA), anti-proliferating cell nuclear antigen antibody was from Abcam (Cambridge, MA, USA) and anti-CXCR4 antibody was from Abcam and R&D Systems (Minneapolis, MN, USA). Anti-PAUF antibody and recombinant PAUF were prepared as described previously (Kim et al., 2009) .
In vitro cancer cell assays Growth rate was measured by cell counting. Cells were plated into 12-well plates at 4 Â 10 4 cells per well and the number of cells was counted using a hemocytometer every 2 days. Migration and invasion assays were performed using 48-well Boyden chambers (Neuroprobe, Gaithersburg, MD, USA). The lower wells of the chamber were filled with standard culture media. The chamber was assembled using polycarbonate filters (Neuroprobe). For invasion assay, polycarbonate filters were coated with Matrigel. Cells in serum-free media (5 Â 10 4 cells per well) were seeded into the upper compartment of the chamber and the chamber was incubated at 37 1C with 5% CO 2 . Chemicals, antibodies or recombinant proteins, when needed, were added in the upper chamber. After incubation for 20 h, cell migration was quantified by counting the number of migrated cells. All assays were carried out in triplicate and the tendency was confirmed by three independent experiments.
Xenograft nude mice analysis
All animal studies were in compliance with the policy of the animal care and use committee of the Korean Research Institute of Bioscience and Biotechnology. For subcutaneous xenografts, 1 Â 10 7 cells were injected subcutaneously into the flanks of 6-week-old BALB/c nude female mice. For orthotopic xenografts, 1 Â 10 6 cells were injected into the body of the pancreas after exposure of the pancreas by abdominal incision. For in vivo bioluminescence imaging, cells were stably transduced with a lentiviral vector harboring the firefly luciferase gene (LentiM1.4-Luci, Macrogen). Bioluminescence imaging of cells and mice was performed by means of the in vivo imaging system IVIS Lumina (Xenogen, Alameda, CA, USA) and data were analysed using Living Image Acquisition and Analysis software (Xenogen). The tumors were recovered from the mice at autopsy, fixed in 4% paraformaldehyde and then embedded in paraffin. Immunostaining analysis of the tumor specimens was performed as described below.
Immunohistochemical analysis
Paraffin-embedded tissue specimens of surgically resected tumors were from patients with pancreatic adenocarcinoma at the Chungnam National University hospital. All patients signed an informed consent approved by the institutional review board of the hospital. Rabbit anti-CXCR4 antibody and affinity-purified rabbit anti-PAUF antibody were used at a dilution of 1:200 and 1:100, respectively. A secondary horseradish peroxidase-conjugated antibody (Dako, Carpinteria, CA, USA) was used for detection. For negative controls, primary antibodies were omitted. The immunohistochemical stains were evaluated by pathologists. The immunohistochemistry grade was scored using a four-point scale: 0, negative staining; 1, weak staining; 2, intermediate staining; and 3, strong staining.
Luciferase reporter assay
Panc-1 cells were transfected with the firefly luciferase reporter plasmid pCRE-Luc, pSRE-Luc or pAP1-Luc (Stratagene, La Jolla, CA, USA) along with the transfection control plasmid, pRL-TK, expressing Renilla luciferase (Promega, Madison, WI, USA) using Lipofectamine (Invitrogen). After 24 h, cells were starved with serum-free Dulbecco's modified Eagle's medium for 16 h, and then treated with 6 nM of recombinant PAUF for 2 h. The activity of firefly-luciferase was determined using Dual-Luciferase Reporter Assay System (Promega) and TD-20/20 Luminometer (Turner Biosystems, Sunnyvale, CA, USA), and then normalized to the activity of Renilla luciferase.
Genome-wide expression analysis
Global gene expression profiles were performed using GeneChip HG-U133 (Affymetrix, West Sarcramento, CA, USA). Expression values of all gene fragments were normalized and analysed using the Microarray Suite 5.0 software (Affymetrix). The Cluster and TreeView programs were used for analysing and visualizing the results of the microarray experiments (Eisen et al., 1998) .
Western blot analysis
Cells lysates were prepared in radioimmunoprecipitation assay buffer and culture supernatants were concentrated by using Microcon centrifugal filters (Millipore, Billerica, MA, USA). Samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Hybond-ECL nitrocellulose membrane (Amersham, Buckinghamshire, Sweden). Membranes were probed with an appropriate primary antibody diluted in Tris-buffered saline Tween-20 containing 5% bovine serum albumin, and then with a secondary horseradish peroxidase-conjugated antibody. Bound antibody was visualized by using enhanced chemiluminescence reagents (Amersham). The intensity of band was quantified and normalized by densitometry using GeneTools image analysis software (Syngene, Cambridge, UK).
Statistical analysis
Data are presented as means±s.e.. Unless otherwise indicated, the Student's t-test was used for statistical analysis, with Po0.05 defined as significant.
